H Mogun
Overview
Explore the profile of H Mogun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
934
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bermas B, Kim S, Huybrechts K, Mogun H, Hernandez-Diaz S, Bateman B, et al.
Lupus
. 2018 Jan;
27(6):1012-1017.
PMID: 29301469
Background: Evidence suggests that continuing hydroxychloroquine (HCQ) during pregnancy in women with systemic lupus erythematosus (SLE) improves outcomes. We sought to describe time trends in the continuation, initiation, and duration...
2.
Solomon D, Brown E, Chandler D, Bower A, Barron R, Mogun H, et al.
Osteoporos Int
. 2014 Jun;
25(9):2255-62.
PMID: 24899104
Unlabelled: Among 125,954 new users of osteoporosis (OP) medications, 77 % of subjects stopped OP medications, and 23 % of subjects added or started a new OP medication during follow-up,...
3.
Bateman B, Hernandez-Diaz S, Huybrechts K, Palmsten K, Mogun H, Ecker J, et al.
BJOG
. 2013 Sep;
120(13):1668-76.
PMID: 24020971
Objective: To determine whether outpatient exposure to calcium-channel blockers (CCBs) at the time of delivery is associated with an increased risk for postpartum haemorrhage (PPH). Design: Cohort study. Setting: United...
4.
Juillerat P, Schneeweiss S, Cook E, Ananthakrishnan A, Mogun H, Korzenik J
Aliment Pharmacol Ther
. 2012 Jun;
36(3):239-47.
PMID: 22670722
Background: Recent data suggest that acid suppressive medications may alter factors central to the pathophysiology of inflammatory bowel diseases (IBD), whether through shifts in the intestinal microbiome due to acid...
5.
Gagne J, Patrick A, Mogun H, Solomon D
Clin Pharmacol Ther
. 2011 Apr;
89(6):880-7.
PMID: 21508938
We examined variations in fracture rates among patients initiated on antidepressant drug treatment as identified from Medicare data in two US states and assessed whether the observed variation could be...
6.
Solomon D, Hochberg M, Mogun H, Schneeweiss S
Osteoporos Int
. 2008 Oct;
20(6):895-901.
PMID: 18843515
Summary: While nitrogen-containing bisphosphonates have been shown to reduce fracture risk in postmenopausal women and men, their safety in the period after a fracture is unclear. In fully adjusted multivariable...
7.
Bohn R, Aledort L, Putnam K, Ewenstein B, Mogun H, Avorn J
Haemophilia
. 2004 Feb;
10(1):63-8.
PMID: 14962222
The impact on the cost of care for haemophilia patients with inhibitors is not well defined. To quantify the effect on health care expenditures associated with inhibitors to factor VIII...
8.
Wang P, Bohn R, Glynn R, Mogun H, Avorn J
J Am Geriatr Soc
. 2002 Feb;
49(12):1685-90.
PMID: 11844004
Objectives: The widespread use of sedative-hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer regimens that may be used preferentially by older...
9.
Knight E, Bohn R, Wang P, Glynn R, Mogun H, Avorn J
Hypertension
. 2001 Oct;
38(4):809-14.
PMID: 11641291
Hypertension remains poorly controlled in the United States. Improvement of its management will require an understanding of the patient characteristics and treatment factors associated with uncontrolled hypertension. We studied antihypertensive...
10.
Wang P, Bohn R, Glynn R, Mogun H, Avorn J
Am J Psychiatry
. 2001 Jun;
158(6):892-8.
PMID: 11384896
Objective: While benzodiazepine treatment is known to increase the risk of hip fracture in older populations, controversy persists over which characteristics of benzodiazepine use (e.g., elimination half-life, dosage, duration of...